IN2012DN00908A - - Google Patents

Info

Publication number
IN2012DN00908A
IN2012DN00908A IN908DEN2012A IN2012DN00908A IN 2012DN00908 A IN2012DN00908 A IN 2012DN00908A IN 908DEN2012 A IN908DEN2012 A IN 908DEN2012A IN 2012DN00908 A IN2012DN00908 A IN 2012DN00908A
Authority
IN
India
Prior art keywords
polypeptides
factor
modified factor
methods
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Brooks Alan
Patel Chandra
Jiang Xiaoqiao
Gritzan Uwe
Apeler Heiner
Wangjun
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN00908(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of IN2012DN00908A publication Critical patent/IN2012DN00908A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/644Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IN908DEN2012 2009-07-31 2010-08-02 IN2012DN00908A (US07119074-20061010-C00048.png)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23055109P 2009-07-31 2009-07-31
PCT/US2010/044177 WO2011014890A1 (en) 2009-07-31 2010-08-02 Modified factor ix polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
IN2012DN00908A true IN2012DN00908A (US07119074-20061010-C00048.png) 2015-04-03

Family

ID=43529743

Family Applications (1)

Application Number Title Priority Date Filing Date
IN908DEN2012 IN2012DN00908A (US07119074-20061010-C00048.png) 2009-07-31 2010-08-02

Country Status (21)

Country Link
US (1) US20120164130A1 (US07119074-20061010-C00048.png)
EP (1) EP2461821A4 (US07119074-20061010-C00048.png)
JP (1) JP2013500726A (US07119074-20061010-C00048.png)
KR (1) KR20120060209A (US07119074-20061010-C00048.png)
CN (1) CN102573890A (US07119074-20061010-C00048.png)
AU (1) AU2010278721A1 (US07119074-20061010-C00048.png)
BR (1) BR112012002072A2 (US07119074-20061010-C00048.png)
CA (1) CA2769258A1 (US07119074-20061010-C00048.png)
CL (1) CL2012000238A1 (US07119074-20061010-C00048.png)
CR (1) CR20120052A (US07119074-20061010-C00048.png)
CU (3) CU20120018A7 (US07119074-20061010-C00048.png)
DO (1) DOP2012000030A (US07119074-20061010-C00048.png)
EA (1) EA201290069A1 (US07119074-20061010-C00048.png)
EC (1) ECSP12011637A (US07119074-20061010-C00048.png)
GT (1) GT201200023A (US07119074-20061010-C00048.png)
IN (1) IN2012DN00908A (US07119074-20061010-C00048.png)
MX (1) MX2012001346A (US07119074-20061010-C00048.png)
PE (1) PE20121643A1 (US07119074-20061010-C00048.png)
SG (1) SG178119A1 (US07119074-20061010-C00048.png)
WO (1) WO2011014890A1 (US07119074-20061010-C00048.png)
ZA (1) ZA201200716B (US07119074-20061010-C00048.png)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2521490T3 (es) 2006-12-15 2014-11-12 Baxter International Inc. Conjugado de factor VIIa - ácido (poli)siálico con una vida media in vivo prolongada.
DK2337849T3 (en) 2008-09-15 2018-10-01 Uniqure Biopharma B V FACTOR IX POLYPEPTIME MUTANT, APPLICATIONS THEREOF AND METHOD OF PRODUCING THEREOF
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
WO2011017055A2 (en) 2009-07-27 2011-02-10 Baxter International Inc. Blood coagulation protein conjugates
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
ES2590679T3 (es) 2009-07-27 2016-11-23 Lipoxen Technologies Limited Glicopolisialilación de proteínas diferentes a proteínas de coagulación de la sangre
DK2598172T3 (da) * 2010-07-30 2019-07-01 Baxalta GmbH Nukleofile katalysatorer til oximforbindelse
MX345608B (es) 2010-12-22 2017-02-07 Baxalta Inc Materiales y metodos para conjugar un derivado de acido graso soluble en agua a una proteina.
CN104144950B (zh) * 2011-12-19 2017-09-05 迪乐方有限责任公司 含有重复的二糖单元的非抗凝的葡糖胺聚糖及其医药用途
CA2892038C (en) * 2012-11-20 2021-12-28 Darrel W. Stafford Methods and compositions for modified factor ix proteins
DK2970424T3 (en) * 2013-03-13 2017-07-31 Lilly Co Eli Modified leptide polypeptides in dogs
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
AU2016301303B2 (en) 2015-08-03 2021-10-07 Bioverativ Therapeutics Inc. Factor IX fusion proteins and methods of making and using same
JP7181855B2 (ja) * 2016-07-27 2022-12-01 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 第ix因子の機能を調節するための組成物及び方法
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044982A1 (en) * 2001-04-25 2003-03-06 Kenneth Chien Method to treat hemophilia by hepatic gene transfer of factor VIII/IX with vesicle vector
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
JP4738346B2 (ja) * 2003-12-03 2011-08-03 ノヴォ ノルディスク アー/エス GlycoPEG化された第IX因子
US8383388B2 (en) * 2006-06-19 2013-02-26 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
ECSP12011637A (es) 2012-02-29
PE20121643A1 (es) 2012-11-25
EP2461821A1 (en) 2012-06-13
EA201290069A1 (ru) 2012-07-30
MX2012001346A (es) 2012-02-17
CU20120018A7 (es) 2012-06-21
EP2461821A4 (en) 2013-07-03
BR112012002072A2 (pt) 2016-11-08
JP2013500726A (ja) 2013-01-10
DOP2012000030A (es) 2012-02-29
GT201200023A (es) 2014-01-27
ZA201200716B (en) 2013-07-31
CR20120052A (es) 2012-06-04
CU20130057A7 (es) 2013-06-28
CU20130058A7 (es) 2013-06-28
WO2011014890A1 (en) 2011-02-03
CL2012000238A1 (es) 2012-10-05
CN102573890A (zh) 2012-07-11
AU2010278721A1 (en) 2012-02-16
SG178119A1 (en) 2012-03-29
CA2769258A1 (en) 2011-02-03
KR20120060209A (ko) 2012-06-11
US20120164130A1 (en) 2012-06-28

Similar Documents

Publication Publication Date Title
IN2012DN00908A (US07119074-20061010-C00048.png)
MX2011007930A (es) Conjugados de insulina cristalina.
MY192475A (en) Modified factor ix polypeptides and uses thereof
MX356282B (es) Composiciones y metodos que comprenden variantes de proteasa.
MX2012003723A (es) Compuestos policiclicos como antagonistas del receptor de acido lisofosfatidico.
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
GEP20146056B (en) Acylated glucagon analogues
MX355543B (es) Macrociclos peptidomiméticos.
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
IN2012DN03883A (US07119074-20061010-C00048.png)
IN2012DN02177A (US07119074-20061010-C00048.png)
IN2012DN00754A (US07119074-20061010-C00048.png)
MX2012007438A (es) Analogo peptidico de oxintomodulina.
MX2013009175A (es) Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas.
JO3635B1 (ar) مركبات صيدلانية صلبة وطرق لانتاجها
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
MX2019003619A (es) Formulaciones de bromocriptina.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX2010010457A (es) Vectores recombinantes de rinovirus.
MX2012013875A (es) Anticuerpos de union sparc en sangre periferica y usos de los mismos.
PH12014501200A1 (en) Bacteriophage gene 3 protein compositions and use as amyloid binding agents
MX2011008179A (es) Peptidos para vacuna.
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma